# Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI

Study · id `cardio:ct-nct07898709` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07898709](<https://clinicaltrials.gov/study/NCT07898709>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07898709

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07898709. Randomized; no masking; primary purpose treatment. Start 2027-01 (anticipated); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07898709, source copy `cardio:ctgov-nct07898709-2026-10-27`, retrieved 2026-10-31)
- Planned start: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07898709, source copy `cardio:ctgov-nct07898709-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT07898709, source copy `cardio:ctgov-nct07898709-2026-10-27`, retrieved 2026-10-31)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT07898709, source copy `cardio:ctgov-nct07898709-2026-10-27`, retrieved 2026-10-31)
- Countries: Egypt (ClinicalTrials.gov record NCT07898709, source copy `cardio:ctgov-nct07898709-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07898709-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
- Condition: No Reflow Phenomenon
- Condition: Reperfusion Injuries, Myocardial
- Condition: Myocardial Infarction
- Condition: STEMI - ST Elevation Myocardial Infarction
- Condition: Coronary Artery Disease (CAD)
- Condition: PCI
- Condition: Sodium Glucose Co-Transporter 2 Inhibitors
- Condition: Empagliflozin
- Condition: Dapagliflozin
- Intervention (Drug): Empagliflozin (SGLT2i)
- Intervention (Drug): dapagliflozin
- Intervention (Drug): Standard medical treatment
- Lead sponsor: Al-Azhar University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: f04ac6902189463b921a94f1f78ef5b8cfdc75ee1fb7578825090d3c781e8422
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
